Loading clinical trials...
Loading clinical trials...
The primary objective of this study is to assess the overall survival (OS) of oral linifanib given as monotherapy once daily (QD) compared to sorafenib given twice daily (BID) per standard of care in ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Abbott
NCT07118202 · Hepatocellular Carcinoma Recurrent
NCT06687941 · Neoplasms, Carcinoma, Hepatocellular, and more
NCT06492395 · Hepatocellular Carcinoma Non-resectable
NCT06707233 · Hepatocellular Carcinoma Non-Resectable
NCT05911633 · Hepatocellular Carcinoma Non-resectable
Site Reference ID/Investigator# 23247
Beverly Hills, California
Site Reference ID/Investigator# 23608
LaVerne, California
Site Reference ID/Investigator# 23852
Orange, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions